Allarity Therapeutics, Inc. logo

Allarity Therapeutics, Inc. (ALLR) Q4 2024 Annual Earnings

ALLR·Reported April 4, 2025·Before market open

Allarity Therapeutics, Inc. reported Q4 2024 revenue of $6.0K (-94.6% YoY). Diluted EPS came in at $-4.73 (+97.3% YoY), beat the $-8.10 consensus by $3.37.

Revenue
$6.0K
Diluted EPS
$-4.73beat by $3.37
Consensus: $-8.10
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0001437749-25-010198

Financial Snapshot

Trailing eight quarters through Q4 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q4 2024 Earnings FAQ

Common questions about Allarity Therapeutics, Inc.'s Q4 2024 earnings report.

Allarity Therapeutics, Inc. (ALLR) reported Q4 2024 earnings on April 4, 2025 before market open.

Allarity Therapeutics, Inc. reported revenue of $6.0K and diluted EPS of $-4.73 for Q4 2024.

EPS beat the consensus estimate of $-8.10 by $3.37.

Compared to the same quarter a year prior, revenue declined 94.6% from $112.0K a year earlier and diluted EPS grew 97.3% from $-175.51.

You can read the 10-K periodic report (0001437749-25-010198) directly on SEC EDGAR. The filing index links above go to sec.gov.